LOS ALTOS, Calif., Jan. 11 /PRNewswire/ -- InteKrin Therapeutics Inc. will present at the 28th Annual JP Morgan Global Healthcare Conference at 4:00 p.m. Pacific Time on Monday, January 11, 2010, to be held at the Westin St. Francis in San Francisco, California. InteKrin Therapeutics' President and CEO Denny Lanfear will present at the conference.
About InteKrin (www.InteKrin.com):
InteKrin Therapeutics is a privately-held clinical stage biopharmaceutical company focused on the development and commercialization of novel drugs for the treatment of diabetes, obesity and metabolic disease. The Company's lead program, INT131, is entering Phase 3 clinical trials for treatment of Type 2 diabetes mellitus (T2DM). This product is a highly potent, non-TZD, selective peroxisome proliferator-activated receptor gamma modulator (SPPARM).
Coming after the first generation TZD full PPAR agonists Actos® (pioglitazone) and Avandia® (rosiglitazone), INT131 is the result of an extensive molecular design effort to overcome the chronic safety problems of bone fracture and CHF risk (represented by fluid retention and edema), while minimizing weight gain and retaining efficacy.
INT131 is a unique, next-generation insulin sensitizer that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of type 2 diabetes. Treating and improving insulin sensitivity in diabetic patients by activating PPAR-gamma is an important therapeutic tool for physicians, providing powerful glucose control and durability of effect. As a SPPARM, INT131 selectively modulates PPAR-gamma, and is ideally positioned to safely reduce insulin resistance, addressing an important unmet medical need. This superior safety profile was demonstrated in a robust Phase 2b clinical study of 366 patients, positioning INT131 as the best in class drug in a $6+ Billion global market.
To learn more about InteKrin, visit www.InteKrin.com.
SOURCE InteKrin Therapeutics Inc.